Citigroup Initiates Coverage On Cabaletta Bio with Buy Rating, Announces Price Target of $22
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Samantha Semenkow has initiated coverage on Cabaletta Bio (NASDAQ:CABA) with a Buy rating and a price target of $22.
September 05, 2023 | 10:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup's initiation of coverage on Cabaletta Bio with a Buy rating and a price target of $22 could potentially boost investor confidence and the stock's price in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. Given Citigroup's reputation, its Buy rating and price target of $22 for CABA could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100